Showing 6811-6820 of 7932 results for "".
- FDA Nod for Ortho Derm's Acne Lotion Altrenohttps://practicaldermatology.com/news/fda-nod-for-ortho-derms-acne-lotion-altreno/2457635/The U.S. Food and Drug Administration (FDA) approved the New Drug Application for Ortho Dermatologic’s Altreno (tretinoin 0.05%) lotion, indicated for the topical treatment of acne vulgaris in patients aged 9 and up. Altreno is expected to be
- Lupin Launches Generic Clobetasol Cream in the UShttps://practicaldermatology.com/news/lupin-launches-generic-clobetasol-cream-in-the-us/2457637/Lupin has launched its Clobetasol Propionate Cream 0.05%, having received approval from the FDA earlier.
- Wake Forest Researchers: #2 in Probiotic Advancementhttps://practicaldermatology.com/news/wake-forest-researchers-2-in-probiotic-advancements/2457638/Scientists at Wake Forest School of Medicine say they have developed a probiotic “cocktail” derived from gut bacteria strains found in infant feces that may help increase the body’s ability to produce short-chain fatty acids (SCFAs). “Short-chain fa
- Merix Pharmaceutical Corp: Releev Cold Sore Treatment Now in Convenience Storeshttps://practicaldermatology.com/news/merit-pharmaceutical-corp-releev-cold-sore-treatment-now-in-convenience-stores/2457644/Merix Pharmaceutical Corp’s Releev®1 Day Cold Sore Symptom Treatment is now available in convenience stores, including 7-Eleven and soon in Circle K in the United States. Releev
- Ortho Dermatologics Resubmits NDA for Duobrii Lotionhttps://practicaldermatology.com/news/ortho-dermatologics-resubmits-nda-for-duobrii-lotion/2457646/Ortho Dermatologics, a division of Bausch Health Companies Inc., has resubmitted a New Drug Application (NDA) to the FDA for Duobrii™ (halobetasol propionate and tazarotene; IDP-118) lotion in the treatment of p
- Revision Skincare Launches DEJ Eye Cream, DEJ Face Creamhttps://practicaldermatology.com/news/revision-launches-dej-eye-cream-dej-face-cream/2457648/Revision Skincare® has created two comprehensive products,DEJ eye cream® and DEJ face cream®, utilizing Pathway Technology and Prebiotic Innovation to provide clinically-proven results and promote long-term skin health, the company says. DEJ eye cream® addresses
- Frequent BCC Linked to Other Cancershttps://practicaldermatology.com/news/frequent-bcc-linked-to-other-cancers/2457651/Basal cell carcinoma may increase risk for the development of other cancers, including blood, breast, colon and prostate cancers, according to a preliminary study by researchers at the Stanford University School of Medicine. "We discovered that people who develop six or more basal ce
- Escalier Biosciences' Doses First PsO Patient with ESR-114; Announces Clinical Advisory Boardhttps://practicaldermatology.com/news/escalier-biosciences-doses-first-patient-with-esr-114-announces-clinical-advisory-board/2457652/The first patient has been dosed in a Phase 1/2a study evaluating Escalier Biosciences’ ESR-114 topical gel for mild-to-moderate psoriasis. "The initiation of this study represents a significant milestone for Escalier as it validates o
- Pulse Biosciences: First Patient Treated in BCC Studyhttps://practicaldermatology.com/news/pulse-biosciences-first-patient-treated-in-bcc-study/2457653/The first patient has been treated in a clinical study to evaluate Nano-Pulse Stimulation (NPS) from Pulse Biosciences, Inc. for
- FDA Committee Recommends Approval of Paratek's Omadacyclinehttps://practicaldermatology.com/news/fda-committee-recommends-approval-of-parateks-omadacycline/2457656/The Antimicrobials Drug Advisory Committee of the FDA voted in favor of the approval of intravenous (IV) and oral omadacycline for the treatment of acute bacterial skin and skin structure infections (ABSSSI) (17-1) and community-acquired bacterial pneumonia (CABP) (14-4). Paratek Pharmaceuticals,